Insights

Cutting-edge RNA technology Capstan Therapeutics utilizes innovative RNA technology, such as the CellSeeker™ tLNP platform, to develop targeted therapies with potential applications in diverse disease areas including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. This cutting-edge approach presents an opportunity to engage with healthcare providers seeking advanced treatment options.

Therapeutic possibilities expansion Capstan's focus on multiplying therapeutic possibilities through in vivo RNA technologies offers a unique proposition for pharmaceutical companies seeking to broaden their product portfolio. Engaging with Capstan could open up avenues for partnerships in developing transformative therapies for unmet medical needs.

Financially robust With a revenue range of $10M - 50M and substantial funding of $175M, Capstan demonstrates financial stability and growth potential. This financial robustness indicates a strong foundation for potential investors or strategic partners looking to capitalize on the biotechnology sector's growth.

Strategic market positioning Capstan's strategic focus on developing therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders aligns with the current market trends prioritizing precision medicine and personalized treatment approaches. This strategic alignment creates sales opportunities with stakeholders aiming to address specific patient populations effectively.

Competitive advantage through technology Capstan's proprietary technology, the CellSeeker™ tLNP platform, provides a competitive edge in the biotechnology research industry. This technological advantage positions Capstan as an appealing partner for companies seeking innovative drug delivery solutions and personalized medicine offerings.

Capstan Therapeutics Email Formats	Example	Percentage
FLast@capstantx.com	JDoe@capstantx.com	99%
FL@capstantx.com	JD@capstantx.com	1%

Capstan Therapeutics Email Formats

Example

Percentage

FLast@capstantx.com

JDoe@capstantx.com

99%

FL@capstantx.com

JD@capstantx.com

Frequently Asked Questions

Where is Capstan Therapeutics's headquarters located?

Capstan Therapeutics's main headquarters is located at San Diego, California US. The company has employees across 3 continents, including North AmericaAsiaEurope.

How much revenue does Capstan Therapeutics generate?

As of October 2024, Capstan Therapeutics's annual revenue reached $15M.

What is Capstan Therapeutics's SIC code NAICS code?

Capstan Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Capstan Therapeutics have currently?

As of October 2024, Capstan Therapeutics has approximately 98 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Technology Officer: P. K.Chief Financial Officer: J. T.Chief Medical Officer: R. F.. Explore Capstan Therapeutics's employee directory with LeadIQ.

What industry does Capstan Therapeutics belong to?

Capstan Therapeutics operates in the Biotechnology Research industry.

What is Capstan Therapeutics's email format?

Capstan Therapeutics's email format typically follows the pattern of . Find more Capstan Therapeutics email formats with LeadIQ.

How much funding has Capstan Therapeutics raised to date?

As of October 2024, Capstan Therapeutics has raised $175M in funding. The last funding round occurred on Mar 20, 2024 for $175M.

When was Capstan Therapeutics founded?

Capstan Therapeutics was founded in 2021.

Capstan Therapeutics

Biotechnology ResearchCalifornia, United States51-200 Employees

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our CellSeeker™ tLNP platform technology comprises proprietary targeted lipid nanoparticles (tLNP) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com.

Company Leadership

P. K.

Chief Technology Officer

Mobile Phone

J. T.

Chief Financial Officer

Mobile Phone

R. F.

Chief Medical Officer

Mobile Phone

J. R.

Vice President Of Translational Medicine

Mobile Phone

A. B.

Founding Chief Scientific Officer And Executive Vice President Of R&d

Mobile Phone

Employee Directory

J. R.

Vice President Of Translational Medicine

Mobile Phone

X. L.

Senior Director, Head Of Cell Engineering

Mobile Phone

G. A.

Vp, Pharmacology & Toxicology

Mobile Phone

S. A. S.

Senior Director - Head Of Product Discovery

Mobile Phone

M. M.

Senior Vice President, Regulatory And Quality

Mobile Phone

Insights

Similar companies to Capstan Therapeutics

NVision Imaging Technologies

Jecure Therapeutics

Ossianix

Circuit Therapeutics

Protagonist Therapeutics